# Royalty Pharma plc (RPRX) FY2026 YTD Q2 P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001802768-26-000015
- Page: https://plicit.ai/financials/rprx/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total income and other revenues**: 1,304,717,000 US dollars
- **Total operating expense, net**: 608,561,000 US dollars
- **Operating income**: 696,156,000 US dollars
- **Total other expense, net**: negative 146,415,000 US dollars
- **Consolidated net income before tax**: 549,741,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net income**: 549,741,000 US dollars
- **Income from financial royalty assets**: 1,233,019,000 US dollars
- **Other royalty income and revenues**: 71,698,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: 70,732,000 US dollars
- **Provision for credit losses on unfunded commitments**: 9,368,000 US dollars
- **Research and development funding expense**: 137,641,000 US dollars
- **General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4)**: 321,377,000 US dollars
- **Financial royalty asset impairment**: 69,443,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $312.57 M; to noncontrolling interests: $237.17 M.